Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Radioembolization in Elderly/ Fragile Patients With mCRC

NCT: NCT05092880 · TERMINATED

NCT IDNCT05092880
StatusTERMINATED
Start Date2022-06-01
Completion2025-09-01

Brief Summary

Radioembolization (RE) is a minimally invasive treatment with administration of radioactive microspheres into the hepatic artery via a microcatheter. Since tumors are preferentially supplied by the hepatic artery, most microspheres get trapped in the tumor. RE has been shown a feasible and safe procedure for the treatment of unresectable CRC liver metastases. These data compare favourably with the toxicity data of capecitabine plus bevacizumab, but this should be validated in a prospective study. The proposed study investigates the efficacy of RE as an alternative, better tolerated and more cost-effective treatment option in elderly or frail patients compared to chronic systemic treatment with comparable progression-free survival.

Frequently Asked Questions

What is Radioembolization in Elderly/ Fragile Patients With mCRC?

Radioembolization in Elderly/ Fragile Patients With mCRC is a clinical trial registered under NCT05092880. Current status: TERMINATED.

What is the status of NCT05092880?

The current status of NCT05092880 (Radioembolization in Elderly/ Fragile Patients With mCRC) is: TERMINATED.

When did Radioembolization in Elderly/ Fragile Patients With mCRC start?

Radioembolization in Elderly/ Fragile Patients With mCRC started on 2022-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.